HALO Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 50.24%. Halozyme Therapeutics's return on equity of 137.42% beat Johnson & Johnson's return on equity of 30.18%.

Halozyme Therapeutics has a consensus price target of $70.38, signalling upside risk potential of 6.84%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 10.36%. Given that Johnson & Johnson has higher upside potential than Halozyme Therapeutics, analysts believe Johnson & Johnson is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.256, which suggesting that the stock is 25.56% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.22% to investors and pays a quarterly dividend of $1.24 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Halozyme Therapeutics's net income of $118.1M is lower than Johnson & Johnson's net income of $11B. Notably, Halozyme Therapeutics's price-to-earnings ratio is 17.52x while Johnson & Johnson's PE ratio is 17.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 7.82x versus 4.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 32.71%. Halozyme Therapeutics's return on equity of 137.42% beat Merck &'s return on equity of 39.02%.

Halozyme Therapeutics has a consensus price target of $70.38, signalling upside risk potential of 6.84%. On the other hand Merck & has an analysts' consensus of $105.02 which suggests that it could grow by 38.24%. Given that Merck & has higher upside potential than Halozyme Therapeutics, analysts believe Merck & is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.256, which suggesting that the stock is 25.56% more volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.16% to investors and pays a quarterly dividend of $0.81 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Merck & quarterly revenues of $15.5B. Halozyme Therapeutics's net income of $118.1M is lower than Merck &'s net income of $5.1B. Notably, Halozyme Therapeutics's price-to-earnings ratio is 17.52x while Merck &'s PE ratio is 11.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 7.82x versus 3.02x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Penumbra has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 12.1%. Halozyme Therapeutics's return on equity of 137.42% beat Penumbra's return on equity of 3.62%.

Halozyme Therapeutics has a consensus price target of $70.38, signalling upside risk potential of 6.84%. On the other hand Penumbra has an analysts' consensus of $318.59 which suggests that it could grow by 7.15%. Given that Penumbra has higher upside potential than Halozyme Therapeutics, analysts believe Penumbra is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.256, which suggesting that the stock is 25.56% more volatile than S&P 500. In comparison Penumbra has a beta of 0.528, suggesting its less volatile than the S&P 500 by 47.181%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Penumbra offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Penumbra pays out -- of its earnings as a dividend.

Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Penumbra quarterly revenues of $324.1M. Halozyme Therapeutics's net income of $118.1M is higher than Penumbra's net income of $39.2M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 17.52x while Penumbra's PE ratio is 280.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 7.82x versus 9.48x for Penumbra. Usually stocks with elevated PS ratios are considered overvalued.

Semler Scientific has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 41.51%. Halozyme Therapeutics's return on equity of 137.42% beat Semler Scientific's return on equity of 37.58%.

Halozyme Therapeutics has a consensus price target of $70.38, signalling upside risk potential of 6.84%. On the other hand Semler Scientific has an analysts' consensus of $71.00 which suggests that it could grow by 104.08%. Given that Semler Scientific has higher upside potential than Halozyme Therapeutics, analysts believe Semler Scientific is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.256, which suggesting that the stock is 25.56% more volatile than S&P 500. In comparison Semler Scientific has a beta of 1.330, suggesting its more volatile than the S&P 500 by 33.038%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Semler Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Semler Scientific pays out -- of its earnings as a dividend.

Halozyme Therapeutics quarterly revenues are $264.9M, which are larger than Semler Scientific quarterly revenues of $12.4M. Halozyme Therapeutics's net income of $118.1M is higher than Semler Scientific's net income of $29.2M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 17.52x while Semler Scientific's PE ratio is 7.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 7.82x versus 4.93x for Semler Scientific. Usually stocks with elevated PS ratios are considered overvalued.